Science & Enterprise subscription

Follow us on Twitter

  • See our infographic on Saturday ... https://t.co/915iuVjrta https://t.co/foiMp01PXB
    about 10 hours ago
  • Results from a clinical trial show a drug approved for a rare lymph node disease can stabilize or improve the condi… https://t.co/E66q37t6Ey
    about 16 hours ago
  • New post on Science and Enterprise: Trial Shows Rare Disease Drug Treats Covid-19 Patients https://t.co/nq3C3i5IwP #Science #Business
    about 16 hours ago
  • NY Times ... Covid-19 Changed How the World Does Science, Together https://t.co/a2GEMqNlgg
    about 1 day ago
  • A smartphone app is collecting individual reports about Covid-19 symptoms and other health conditions to provide ea… https://t.co/gxdMGhThvO
    about 2 days ago

Please share Science & Enterprise

Say Hello to HelloToken

Hello name tag

(Eviatar Bach, Wikimedia Commons)

25 May 2016. Science & Enterprise, as regular visitors know, is a business and science news blog that tries to make the visiting experience both professional and productive. We’re also a business enterprise, and need to generate income to support our work. We’re starting a feature on Science & Enterprise that we believe will add to our income, while respecting the visitors’ time and intelligence.

The new feature is HelloToken, provided by a start-up enterprise of the same name spun-off from Harvard University. HelloToken  presents brief one-question surveys from sponsors as you join Science & Enterprise. After you choose an answer, the question disappears. That’s it. Questions are unobtrusive and multiple choice; just make your choice.

You can opt out from answering by clicking off the question, but by responding you help keep Science & Enterprise freely available. As part of the deal, we will remove much of our current advertising on posts and pages.

By the way, HelloToken incubated at Harvard’s Innovation Lab or i-Lab, an entrepreneurial center on campus. We reported on i-Lab’s opening in 2011, and just last week told about an i-Lab spin-off enterprise developing diagnostics for HIV infection.

As always, we welcome your feedback. Let us know your comments, pro or con, at sciencebusiness@technewslit.com.

*     *     *

Please share Science & Enterprise ...

Comments are closed.